Endocapsular equator rings prevent posterior capsular opacification

Article

The 9.5 mm E-ring prevents posterior capsular opacification (PCO) in patients after cataract surgery.

An investigation published in the Archives of Ophthalmology shows that the 9.5 mm E-ring prevents posterior capsular opacification (PCO) in patients after cataract surgery.

Dr Tsutomu Hara et al., Hara Eye Hospital, Utsunomiya, Japan, studied 51 eyes that underwent cataract surgery and E-ring implantation. The patients were divided into three groups. Group 1 consisted of 14 patients who received an E-ring and IOL in one eye and just an IOL in the fellow eye. Group 2 included 37 eyes of 23 patients who received an E-ring and IOL in one or both eyes and 37 age-matched control eyes who received an IOL implant only. There was a follow-up period of 2 to 7 years and the PCO value was assessed using the Hayashi method.

The results found that, 2 years postoperatively, the PCO value in the central area of the eyes with an E-ring were considerably lower in group 1 than in the control eyes.

Patients who received an E-ring did not require additional postoperative Nd:YAG laser posterior capsulotomy compared with 23 of the 51 control eyes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.